×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

Do you want to link to this External Site and leave Amgen.com?

YOU ARE NOW LEAVING AMGEN'S WEB SITE. Amgen takes no responsibility for, and exercises no control over, the organizations, views, or accuracy of the information contained on this server or site.

×

 

Jeff Reagan

Scientific Director
Cardiometabolic Disorders

Jeff Reagan received his Ph.D. in chemistry from Yale University. He pursued postdoctoral studies at the Yale University School of Medicine in the Department of Neurobiology, studying the molecular pharmacology of olfaction.  Jeff joined Sandoz/Novartis to work on G protein-coupled receptor (GPCR) pharmacology. After joining Affymax, he extended his work on the molecular pharmacology of GPCRs. In 2001 he joined Tularik (acquired by Amgen in 2004) and worked in diabetes, nephrology, and cardiovascular disease with a specific emphasis on systolic heart failure. His principal area of interest is applying the tools of molecular pharmacology and mathematical modeling to the treatment of heart failure and other metabolic disorders.

Featured Publications

Wang W.; Zhang L.; Battiprolu P.K.; Fukushima A.; Nguyen K.; Milner K.; Gupta A.; Altamimi T.; Byrne N.; Mori J.; Alrob O.A.; Wagg C.; Fillmore N.; Wang S.-H.; Liu D.M.; Fu A.; Lu J.Y.; Chaves M.; Motani A.; Ussher J.R.; Reagan J.D.; Dyck J.R.B.; Lopaschuk G.D. (2019) Malonyl CoA Decarboxylase Inhibition Improves Cardiac Function Post-Myocardial Infarction. JACC: Basic to Translational Science. 4 (3) (pp 385-400) https://basictranslational.onlinejacc.org/content/4/3/385

Murakoshi, M., Kuwabara, H., Nagasaki, M., Maeda, H., Xiong, Y., Reagan, J.D., Nara, F. (2017) Discovery and Pharmacological effects of a novel GPR142 antagonist. J. Receptors and Signal Transduction 37(3):290-296. https://www.tandfonline.com/doi/full/10.1080/10799893.2016.1247861

Henley, C., Yang, Y., Davis, J., Lu, J. Y., Morony, S., Fan, W., Florio, M., Sun, B., Shatzen, E., Pretorius, J. K., Richards, W. G., St Jean, D. J., Fotsch, C., Reagan, J. D. (2011)  Discovery of a Calcimimetic With Differential Effects on PTH and Calcitonin Secretion.  J Pharmacol Exp Ther  337: 681-691 http://jpet.aspetjournals.org/content/337/3/681.long

Education

Postdoctoral Fellowship, Molecular Neurobiology, Yale University School of Medicine
Ph.D., Chemistry, Yale University
B.S., Chemistry, Florida International University